Quantcast

Latest Sirolimus Stories

2010-03-17 14:08:00

WATERLOO, Belgium, March 17, 2010 /PRNewswire/ -- - SORT OUT III Data Presented at American College of Cardiology Meeting in Atlanta and Published in the Lancet Investigators reported the long-term follow-up of the largest randomized comparison between the CYPHER(R) Sirolimus-eluting Coronary Stent and Medtronic's Endeavor(R) Stent highlighting significant and sustained clinical differences. These important findings were presented at the American College of Cardiology annual...

2010-03-17 11:11:29

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect. According to the study team, this discovery has broad clinical implications in the fight against cancer and could affect treatment of lymphoma and many other forms of the disease, including prostate cancer, breast cancer, colorectal...

2010-02-25 08:14:22

Study suggests potential new use for immunosuppressive drug Rapamycin, a drug that keeps the immune system from attacking transplanted organs, may have another exciting use: fighting Alzheimer's disease. Rapamycin rescued learning and memory deficits in a mouse model of Alzheimer's, a team from The University of Texas Health Science Center at San Antonio reported Tuesday (Feb. 23). The study, in the Journal of Biological Chemistry, offers the first evidence that the drug is able to reverse...

2010-02-04 08:00:00

JAMAICA PLAIN, Mass., Feb. 4 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD). The Phase I study, "A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients with Advanced Neovascular Age-Related Macular Degeneration"...

2010-01-25 15:38:02

 Research performed at UC Santa Barbara points to the drug rapamycin as a potential treatment for kidney disease. The study builds on past research and shows that studies performed on mice are more likely to translate to humans than previously thought. The results are published in the current online issue of the Journal of the American Society of Nephrology. Over 600,000 people in the U.S., and 12 million worldwide, are affected by the inherited kidney disease known as ADPKD, short for...

ad5d02e6dacc29a83da644044fdb273f1
2010-01-10 14:03:33

Tuberous sclerosis, commonly associated with autism, is linked to defects in axon guidance Studying a rare disorder known as tuberous sclerosis complex (TSC), researchers at Children's Hospital Boston add to a growing body of evidence suggesting that autism spectrum disorders, which affect 25 to 50 percent of TSC patients, result from a miswiring of connections in the developing brain, leading to improper information flow. The finding may also help explain why many people with TSC have...

2010-01-05 07:00:00

LA JOLLA, Calif., Jan. 5 /PRNewswire/ -- Intellikine, Inc. has initiated a Phase I clinical trial for its targeted anticancer drug INK128, a novel orally-available small molecule inhibitor of both the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway. "Advancing INK128 to this point is a significant achievement for Intellikine," said Troy Wilson, Ph.D., J.D., President and CEO of Intellikine. "INK128 is the first drug resulting from our internal discovery...

2009-12-07 14:51:09

After suffering heart attacks, patients often receive stents designed to hold their arteries open. Some of these stents release drugs that are meant to halt tissue growth in arteries, but can have life-threatening side effects such as increasing the likelihood of blood clots and heart attacks. Now a team of researchers in the MIT-Harvard Division of Health Sciences and Technology has developed a computer model that explains why those drugs (which include rapamycin and its analogs as well as...

2009-12-06 17:35:00

A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology's (ASH) annual meeting on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial Convention Center, Room 243-245, 5:45 pm CT). The...

2009-12-01 10:32:00

FORT LAUDERDALE, Fla., Dec. 1 /PRNewswire/ -- OrbusNeich today announced the initiation of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent). A prospective, randomized, multicenter study, REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt) will enroll 180 patients at up to 20 sites in Asia, Australia, Europe and South America. The primary objective is to demonstrate the safety and...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related